Naltrexon Hcl Walter Ritter (Naltrexone Hydrochloride)

Naltrexone hydrochloride is used in the management of substance‑use disorders, acting on opioid receptors to reduce craving and relapse.

• Alcohol dependence: Helps reduce the desire to drink and supports abstinence when used as part of a comprehensive treatment program.
• Opioid dependence relapse prevention: Blocks the euphoric effects of opioids, decreasing the likelihood of relapse after detoxification.
• Mixed dependence (alcohol and opioids): Assists in controlling cravings for both substances when patients present with co‑occurring dependence.

• Naltrexone hydrochloride acts as a competitive antagonist at the μ‑, κ‑ and δ‑opioid receptors. By binding to these receptors without activating them, it blocks the effects of both endogenous opioids and exogenous opioid agonists, thereby diminishing reinforcement, craving and the physiological response associated with alcohol and opioid use. The blockade is dose‑dependent and reversible, allowing normal opioid signaling to resume after the drug is cleared.

Naltrexone hydrochloride may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild to moderate stomach upset that may occur shortly after dosing.
• Headache: transient cranial discomfort, often resolving without intervention.
• Dizziness: sensation of light‑headedness or imbalance, usually temporary.
• Fatigue: feeling of tiredness or reduced energy, may affect daily activities.

Serious or Rare Side Effects

• Hepatotoxicity: significant elevation of liver enzymes or liver injury, requiring monitoring of hepatic function.
• Severe allergic reaction: rash, itching, swelling of face or throat, or anaphylaxis, needing immediate medical attention.
• Depression or suicidal thoughts: emergence or worsening of mood disorders, necessitating prompt evaluation.

When prescribing naltrexone hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

• Liver function: assess baseline hepatic enzymes and monitor periodically during therapy.
• Concomitant opioid use: avoid initiating treatment in patients currently receiving opioid agonists to prevent precipitated withdrawal.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Renal impairment: adjust monitoring in patients with severe kidney disease.
• Alcohol intake: advise patients to abstain from alcohol before starting therapy to reduce risk of hepatotoxicity.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Naltrexone hydrochloride can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Opioid analgesics: concurrent use may precipitate acute withdrawal and diminish analgesia.
• Opioid agonist therapy (e.g., methadone, buprenorphine): may reduce therapeutic effect and cause destabilization.

Moderate Interactions (Monitor Closely)

• Hepatotoxic drugs (e.g., isoniazid, acetaminophen): combined use may increase risk of liver injury.
• CNS depressants (e.g., benzodiazepines): additive sedation may occur.
• Alcohol: concurrent consumption can exacerbate hepatic stress.